Business
Ocumetics Begins Patient Recruitment for First-In-Human Clinical Study of Accommodating Intraocular Lens
(TheNewswire) Calgary, Alberta – TheNewswire - August 5, 2025 - Ocumetic...
About this update from Ocumetics Technology Corp
[{"type":"text","content":"Ocumetics Begins Patient Recruitment for First-In-Human Clinical Study of Accommodating Intraocular Lens\n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Calgary, Alberta –\n \n\n TheNewswire -\n \n\n August 5, 2025\n \n\n -\nOcumetics Technology Corp\n \n\n .\n \n\n (“Ocumetics” or the “Company”)\n(TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced\nophthalmic technology, is pleased to announce\n \n\n the commencement of patient recruitment for its highly anticipated\nfirst-in-human (“FIH”) study of the Ocumetics accommodating\nintraocular lens (the “Ocumetics Lens”).  Patient recruitment is\nexpected to be completed in approximately 7days.\n \n\n\n\n “We are thrilled to begin recruiting patients for\nthis historic study at our clinical partner site in Mexico City,”\nsaid Dean Burns, President and CEO of Ocumetics.  “Our\nfirst-in-human clinical study will primarily assess the safety of the\nOcumetics Lens and secondarily evaluate surgical technique, distance\nacuity and any accommodative effects. This is another significant step\ntoward our goal of restoring clear distance and near vision without\nglasses after cataract surgery.”\n \n\n\n\n Unlike traditional monofocal and multifocal intraocular\nlenses, the Ocumetics Lens is engineered to change its power in\nresponse to the brain’s attempt to visualize items in our\nenvironment at any distance.\n \n\n\n\n Implantations will begin after patient recruitment,\nfinal site inspection, and surgeon training are completed.\n \n\n Results of the FIH clinical study will be\ninstrumental in obtaining regulatory approval of larger, future\nstudies and bringing the Ocumetics Lens to the market.\n \n\n\n\n Ocumetics invites investors, partners, and the medical\ncommunity to follow its progress as this landmark study\nunfolds.\n \n\n\n\n About Ocumetics\n \n\n\n\n Ocumetics Technology Corp.\n \n\n (\n \n\n TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO)\nis a Canadian research and product development company that\n \n\n is dedicated to developing advanced vision\ncorrection solutions that enhance the quality of life for patients.\n Through innovative research and development, Ocumetics aims to\ntransform the field of ophthalmology with state-of-the-art i...